The international prognostic scoring system does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

Haematologica

Volumn 99, Issue 4, 2014, Pages

  Hernández Boluda, Juan Carlos ^a   Pereira, Arturo ^b   Gómez, Montse ^a   Boqué, Concepción ^c   Ferrer Marín, Francisca ^d   Raya, José María ^e   García Gutiérrez, Valentín ^f   Kerguelen, Ana ^g   Xicoy, Blanca ^h   Barba, Pere ⁱ   Martínez, Jesús ^j   Luño, Elisa ^k   Alvarez Larrán, Alberto ^l   Martínez López, Joaquín ^m   Arbelo, Elisa ⁿ   Besses, Carles ^l  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL DEL MAR   (Spain)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

more..

Author keywords

IPSS; Post ET myelofibrosis; Post PV myelofibrosis; Prognostic factors; Survival

Indexed keywords

ANTIANEMIC AGENT; DANAZOL; HYDROXYUREA; IMMUNOMODULATING AGENT; JANUS KINASE INHIBITOR; RUXOLITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; CARDIOVASCULAR DISEASE; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; POLYCYTHEMIA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SPLENECTOMY; THROMBOCYTHEMIA; VERY ELDERLY; COMPLICATION; MORTALITY; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS;

HUMANS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84897414330     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.101733     Document Type: Letter

References (13)

1. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118(3):786-90.
2. Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, Saumell S, Salar A, Abella E, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146(5):504-9.
3. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer. 2006;106(9):1985-9.
4. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383-7.
5. Guglielmelli P, Barosi G, Pieri L, Antonioli E, Bosi A, Vannucchi AM. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica. 2009;94(1):144-6.
6. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901.
7. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82-8.
8. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;(94):496-509.
9. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-53.
10. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-7.
11. Morel P, Duhamel A, Hivert B, Stalniekiewicz L, Demory JL, Dupriez B. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood. 2010;115(22):4350-5.
12. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112(12):2726-32.
13. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-93.